Virtual Reality and Cranial Nerve Neuromodulation to Manage Chronic Pain

What this study is about

In Canada, veterans suffer from chronic pain at twice the rate of the general population. This pain is often linked to post-traumatic stress disorder (PTSD), and both have a major impact on their quality of life. The autonomic nervous system (ANS) plays a key role in these pathologies, making its modulation a promising therapeutic target. Virtual reality (VR) is already being used to alleviate pain and PTSD in veterans, mainly by modulating ANS reactivity. Two types of VR exist: prolonged exposure (desensitization) and the calming effect, the latter being better tolerated and more suitable for rebalancing the ANS. However, its effects on pain remain modest and temporary. To reinforce these benefits, it is proposed to combine VR with a new approach called cranial nerve non-invasive neuromodulation (CN-NINM), an innovative technique that allows the generation of a direct flow of neuronal impulses via the stimulation of the tongue. The goal of this project is therefore to document the efficacy of VR and the combination of VR and CN-NINM on pain and ANS in veterans suffering from chronic pain and PTSD. VR, CN-NINM and the combination of the two will be applied for 20 minutes. Clinical pain, experimental pain and ANS reactivity will be assessed before and after the interventions. At the end of this study, it is expected that the investigators will be able to document the type of effect CN-NINM could have, and that it could become a complementary therapeutic option.

Who can join (things the study team will check)

✅ You may be able to join if…

• Be a veteran;
• Be ≥30 years old;
• Have a diagnosis of chronic musculoskeletal pain (pain > 6 months);
• Have been diagnosed with PTSD by a health professional and/or have a PTSD Checklist for DSM-5 (PCL-5) score > 30/80 and
• Speak English or French.

🚫 You may not be able to join if…

• Bipolar disorder, psychosis;
• Neuropathic pain (based on the Neuropathic Pain Diagnosis and Questionnaire (DN4));
• Visual disorders or photosensitivity, color blindness;
• Epilepsy, motion sickness and
• Any containdications to CN-NINM.

Where this trial is running

• Centre de recherche sur le vieillissement (CdRV), Sherbrooke, Quebec, Canada

Who to contact

Guillaume Léonard, PhD · 819-821-8000 · guillaume.leonard2@usherbrooke.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07065396.